Podoplanin, α-Smooth Muscle Actin or S100A4 Expressing Cancer-Associated Fibroblasts Are Associated with Different Prognosis in Colorectal Cancers
The interactions between the tumor microenvironment and tumor cells determine the behavior of the primary tumors. Whether cancer-associated fibroblasts (CAF) have a tumor progressive or a protective role likely depends on the type of tumor cells and the CAF subpopulation. In the present study, we an...
Saved in:
Published in | Journal of Korean medical science Vol. 28; no. 9; pp. 1293 - 1301 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Korea (South)
The Korean Academy of Medical Sciences
01.09.2013
대한의학회 |
Subjects | |
Online Access | Get full text |
ISSN | 1011-8934 1598-6357 1598-6357 |
DOI | 10.3346/jkms.2013.28.9.1293 |
Cover
Abstract | The interactions between the tumor microenvironment and tumor cells determine the behavior of the primary tumors. Whether cancer-associated fibroblasts (CAF) have a tumor progressive or a protective role likely depends on the type of tumor cells and the CAF subpopulation. In the present study, we analyzed the prognostic significance of CAF subpopulations in colorectal cancer (CRC). CAF phenotypes were analyzed in 302 CRC patients by using antibodies against podoplanin (PDPN), α-smooth muscle actin (α-SMA), and S100A4. The relationship between the CAF phenotypes and 11 clinicopathological parameters were evaluated and their prognostic significance was analyzed from the disease-free and overall survival times. We observed that at the tumor invasive front, PDPN CAFs were present in 40% of the cases, and S100A4 or α-SMA CAFs were detected in all the cases. PDPN/S100A4 and α-SMA/S100A4 dual-stained CAFs were observed in 10% and 40% of the cases, respectively. The PDPN(+) CAFs were associated with 6 favorable clinicopathological parameters and prolonged disease-free survival time. The PDPN(-)/α-SMA(high) CAFs were associated with 6 aggressive clinicopathological parameters and tended to exhibit shorter disease-free survival time. On the other hand, the PDPN(-)/S100A4(high) CAFs were associated with 2 tumor progression parameters, but not with disease prognosis. The PDPN(+) CAF phenotype is distinct from the α-SMA or S100A4 CAFs in that it is associated with less aggressive tumors and a favorable prognosis, whereas the PDPN(-)/α-SMA(high) or PDPN(-)/S100A4(high) CAFs are associated with tumor progression in CRC. These findings suggest that CAFs can be a useful prognostic biomarker or potential targets of anti-cancer therapy in CRC. |
---|---|
AbstractList | The interactions between the tumor microenvironment and tumor cells determine the behavior of the primary tumors. Whether cancer-associated fibroblasts (CAF) have a tumor progressive or a protective role likely depends on the type of tumor cells and the CAF subpopulation. In the present study, we analyzed the prognostic significance of CAF subpopulations in colorectal cancer (CRC). CAF phenotypes were analyzed in 302 CRC patients by using antibodies against podoplanin (PDPN), α-smooth muscle actin (α-SMA), and S100A4. The relationship between the CAF phenotypes and 11 clinicopathological parameters were evaluated and their prognostic significance was analyzed from the disease-free and overall survival times. We observed that at the tumor invasive front, PDPN CAFs were present in 40% of the cases, and S100A4 or α-SMA CAFs were detected in all the cases. PDPN/S100A4 and α-SMA/S100A4 dual-stained CAFs were observed in 10% and 40% of the cases, respectively. The PDPN(+) CAFs were associated with 6 favorable clinicopathological parameters and prolonged disease-free survival time. The PDPN(-)/α-SMA(high) CAFs were associated with 6 aggressive clinicopathological parameters and tended to exhibit shorter disease-free survival time. On the other hand, the PDPN(-)/S100A4(high) CAFs were associated with 2 tumor progression parameters, but not with disease prognosis. The PDPN(+) CAF phenotype is distinct from the α-SMA or S100A4 CAFs in that it is associated with less aggressive tumors and a favorable prognosis, whereas the PDPN(-)/α-SMA(high) or PDPN(-)/S100A4(high) CAFs are associated with tumor progression in CRC. These findings suggest that CAFs can be a useful prognostic biomarker or potential targets of anti-cancer therapy in CRC.The interactions between the tumor microenvironment and tumor cells determine the behavior of the primary tumors. Whether cancer-associated fibroblasts (CAF) have a tumor progressive or a protective role likely depends on the type of tumor cells and the CAF subpopulation. In the present study, we analyzed the prognostic significance of CAF subpopulations in colorectal cancer (CRC). CAF phenotypes were analyzed in 302 CRC patients by using antibodies against podoplanin (PDPN), α-smooth muscle actin (α-SMA), and S100A4. The relationship between the CAF phenotypes and 11 clinicopathological parameters were evaluated and their prognostic significance was analyzed from the disease-free and overall survival times. We observed that at the tumor invasive front, PDPN CAFs were present in 40% of the cases, and S100A4 or α-SMA CAFs were detected in all the cases. PDPN/S100A4 and α-SMA/S100A4 dual-stained CAFs were observed in 10% and 40% of the cases, respectively. The PDPN(+) CAFs were associated with 6 favorable clinicopathological parameters and prolonged disease-free survival time. The PDPN(-)/α-SMA(high) CAFs were associated with 6 aggressive clinicopathological parameters and tended to exhibit shorter disease-free survival time. On the other hand, the PDPN(-)/S100A4(high) CAFs were associated with 2 tumor progression parameters, but not with disease prognosis. The PDPN(+) CAF phenotype is distinct from the α-SMA or S100A4 CAFs in that it is associated with less aggressive tumors and a favorable prognosis, whereas the PDPN(-)/α-SMA(high) or PDPN(-)/S100A4(high) CAFs are associated with tumor progression in CRC. These findings suggest that CAFs can be a useful prognostic biomarker or potential targets of anti-cancer therapy in CRC. The interactions between the tumor microenvironment and tumor cells determine the behavior of the primary tumors. Whether cancer-associated fibroblasts (CAF) have a tumor progressive or a protective role likely depends on the type of tumor cells and the CAF subpopulation. In the present study, we analyzed the prognostic significance of CAF subpopulations in colorectal cancer (CRC). CAF phenotypes were analyzed in 302 CRC patients by using antibodies against podoplanin (PDPN), α-smooth muscle actin (α-SMA), and S100A4. The relationship between the CAF phenotypes and 11 clinicopathological parameters were evaluated and their prognostic significance was analyzed from the disease-free and overall survival times. We observed that at the tumor invasive front, PDPN CAFs were present in 40% of the cases, and S100A4 or α-SMA CAFs were detected in all the cases. PDPN/S100A4 and α-SMA/S100A4 dual-stained CAFs were observed in 10% and 40% of the cases, respectively. The PDPN(+) CAFs were associated with 6 favorable clinicopathological parameters and prolonged disease-free survival time. The PDPN(-)/α-SMA(high) CAFs were associated with 6 aggressive clinicopathological parameters and tended to exhibit shorter disease-free survival time. On the other hand, the PDPN(-)/S100A4(high) CAFs were associated with 2 tumor progression parameters, but not with disease prognosis. The PDPN(+) CAF phenotype is distinct from the α-SMA or S100A4 CAFs in that it is associated with less aggressive tumors and a favorable prognosis, whereas the PDPN(-)/α-SMA(high) or PDPN(-)/S100A4(high) CAFs are associated with tumor progression in CRC. These findings suggest that CAFs can be a useful prognostic biomarker or potential targets of anti-cancer therapy in CRC. The interactions between the tumor microenvironment and tumor cells determine the behavior of the primary tumors. Whether cancer-associated fibroblasts (CAF) have a tumor progressive or a protective role likely depends on the type of tumor cells and the CAF subpopulation. In the present study, we analyzed the prognostic significance of CAF subpopulations in colorectal cancer (CRC). CAF phenotypes were analyzed in 302 CRC patients by using antibodies against podoplanin (PDPN), α-smooth muscle actin (α-SMA),and S100A4. The relationship between the CAF phenotypes and 11 clinicopathological parameters were evaluated and their prognostic significance was analyzed from the disease-free and overall survival times. We observed that at the tumor invasive front,PDPN CAFs were present in 40% of the cases, and S100A4 or α-SMA CAFs were detected in all the cases. PDPN/S100A4 and α-SMA/S100A4 dual-stained CAFs were observed in 10% and 40% of the cases, respectively. The PDPN+ CAFs were associated with 6 favorable clinicopathological parameters and prolonged disease-free survival time. The PDPN−/α-SMAhigh CAFs were associated with 6 aggressive clinicopathological parameters and tended to exhibit shorter disease-free survival time. On the other hand, the PDPN−/S100A4high CAFs were associated with 2 tumor progression parameters, but not with disease prognosis. The PDPN+ CAF phenotype is distinct from the α-SMA or S100A4 CAFs in that it is associated with less aggressive tumors and a favorable prognosis, whereas the PDPN−/α-SMAhigh or PDPN−/S100A4high CAFs are associated with tumor progression in CRC. These findings suggest that CAFs can be a useful prognostic biomarker or potential targets of anti-cancer therapy in CRC. KCI Citation Count: 1 The interactions between the tumor microenvironment and tumor cells determine the behavior of the primary tumors. Whether cancer-associated fibroblasts (CAF) have a tumor progressive or a protective role likely depends on the type of tumor cells and the CAF subpopulation. In the present study, we analyzed the prognostic significance of CAF subpopulations in colorectal cancer (CRC). CAF phenotypes were analyzed in 302 CRC patients by using antibodies against podoplanin (PDPN), α-smooth muscle actin (α-SMA), and S100A4. The relationship between the CAF phenotypes and 11 clinicopathological parameters were evaluated and their prognostic significance was analyzed from the disease-free and overall survival times. We observed that at the tumor invasive front, PDPN CAFs were present in 40% of the cases, and S100A4 or α-SMA CAFs were detected in all the cases. PDPN/S100A4 and α-SMA/S100A4 dual-stained CAFs were observed in 10% and 40% of the cases, respectively. The PDPN + CAFs were associated with 6 favorable clinicopathological parameters and prolonged disease-free survival time. The PDPN - /α-SMA high CAFs were associated with 6 aggressive clinicopathological parameters and tended to exhibit shorter disease-free survival time. On the other hand, the PDPN - /S100A4 high CAFs were associated with 2 tumor progression parameters, but not with disease prognosis. The PDPN + CAF phenotype is distinct from the α-SMA or S100A4 CAFs in that it is associated with less aggressive tumors and a favorable prognosis, whereas the PDPN - /α-SMA high or PDPN - /S100A4 high CAFs are associated with tumor progression in CRC. These findings suggest that CAFs can be a useful prognostic biomarker or potential targets of anti-cancer therapy in CRC. |
Author | Choi, Song-Yi Chae, Hee Bok Kim, Nayoung Lee, Taek-Gu Lee, Eun Jeoung Youn, Sei Jin Lee, Sang-Jeon Sung, Rohyun Yoon, Soon Man Park, Seon Mee |
AuthorAffiliation | 2 Department of Surgery, Chungbuk National University College of Medicine, Cheongju, Korea 1 Department of Pathology, Chungbuk National University College of Medicine, Cheongju, Korea 4 Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Korea 3 Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea |
AuthorAffiliation_xml | – name: 4 Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Korea – name: 1 Department of Pathology, Chungbuk National University College of Medicine, Cheongju, Korea – name: 3 Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea – name: 2 Department of Surgery, Chungbuk National University College of Medicine, Cheongju, Korea |
Author_xml | – sequence: 1 givenname: Song-Yi surname: Choi fullname: Choi, Song-Yi organization: Department of Pathology, Chungbuk National University College of Medicine, Cheongju, Korea – sequence: 2 givenname: Rohyun surname: Sung fullname: Sung, Rohyun organization: Department of Pathology, Chungbuk National University College of Medicine, Cheongju, Korea – sequence: 3 givenname: Sang-Jeon surname: Lee fullname: Lee, Sang-Jeon organization: Department of Surgery, Chungbuk National University College of Medicine, Cheongju, Korea – sequence: 4 givenname: Taek-Gu surname: Lee fullname: Lee, Taek-Gu organization: Department of Surgery, Chungbuk National University College of Medicine, Cheongju, Korea – sequence: 5 givenname: Nayoung orcidid: 0000-0002-9397-0406 surname: Kim fullname: Kim, Nayoung organization: Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea – sequence: 6 givenname: Soon Man surname: Yoon fullname: Yoon, Soon Man organization: Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Korea – sequence: 7 givenname: Eun Jeoung surname: Lee fullname: Lee, Eun Jeoung organization: Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Korea – sequence: 8 givenname: Hee Bok orcidid: 0000-0002-9711-6434 surname: Chae fullname: Chae, Hee Bok organization: Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Korea – sequence: 9 givenname: Sei Jin surname: Youn fullname: Youn, Sei Jin organization: Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Korea – sequence: 10 givenname: Seon Mee surname: Park fullname: Park, Seon Mee organization: Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Korea |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24015033$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART001802018$$DAccess content in National Research Foundation of Korea (NRF) |
BookMark | eNp9UktuFDEQtVAQ-cAJkJCXLOjGdvXPG6TWkECkICIS1pbH7Z440213bA8k5-AkXIQz4c6E4bNg5ZLrfcqud4j2rLMaoeeU5ABF9fp6PYacEQo5a3KeU8bhETqgJW-yCsp6L9WE0qzhUOyjwxCuCWFlyeAJ2mcFoSUBOEDfzl3npkFaY1_hH9-zi9G5eIU_bIIaNG5VNBY7jy8oIW2Bj28nr0MwdoUX0irtszYEp4yMusMnZundcpAhBtz6RP7d-mqS5lvT99prG_G5dyvrggk4qS_c4LxWUQ4PmuEpetzLIehnD-cR-nxyfLl4n519fHe6aM8yVUATM7osZcNYB6qrK6arkirS90A4mSuquGx6SZgEArwqCANa1MC7oiuV6tMVHKGXW13re7FWRjhp7s-VE2sv2k-Xp6KsIfES9M0WOm2Wo-5UeoWXg5i8GaW_uyf-3bHmKsl8EVBXQJP3zmvy7majQxSjCUoP6ee12wSRPNICE3Ye68WfXjuTX0tLANgClHcheN3vIJSIORpijoaYoyFYI7iYo5FY_B-WMlFG4-aBzfBf7k_6osFq |
CitedBy_id | crossref_primary_10_1016_j_canlet_2021_07_006 crossref_primary_10_18632_oncotarget_20074 crossref_primary_10_18632_oncotarget_20076 crossref_primary_10_3390_cancers13081759 crossref_primary_10_17116_patol20218304122 crossref_primary_10_1097_MD_0000000000015164 crossref_primary_10_1016_j_cca_2016_08_008 crossref_primary_10_1016_j_bj_2020_09_006 crossref_primary_10_1016_j_dld_2022_12_007 crossref_primary_10_3390_cancers14184394 crossref_primary_10_1002_cam4_1704 crossref_primary_10_1038_s41388_024_02953_1 crossref_primary_10_1186_s12964_023_01125_0 crossref_primary_10_1186_s12929_024_01099_2 crossref_primary_10_7759_cureus_53949 crossref_primary_10_3390_cancers13020183 crossref_primary_10_1158_0008_5472_CAN_21_0614 crossref_primary_10_3389_fcell_2021_733270 crossref_primary_10_3892_ol_2017_7335 crossref_primary_10_1038_s41467_021_27599_5 crossref_primary_10_2217_fon_2017_0054 crossref_primary_10_1007_s13277_016_5293_6 crossref_primary_10_1159_000531695 crossref_primary_10_18632_oncotarget_7445 crossref_primary_10_3390_cancers12102949 crossref_primary_10_1002_path_5224 crossref_primary_10_3390_cancers13143466 crossref_primary_10_1089_omi_2020_0023 crossref_primary_10_1093_ajcp_aqae145 crossref_primary_10_3892_ol_2018_8097 crossref_primary_10_1038_s41416_020_0973_9 crossref_primary_10_18632_oncotarget_19869 crossref_primary_10_1002_cac2_12291 crossref_primary_10_1007_s13193_022_01653_0 crossref_primary_10_1097_PAS_0000000000002075 crossref_primary_10_1136_jcp_2024_209604 crossref_primary_10_1038_s41392_019_0100_7 crossref_primary_10_32604_biocell_2023_030541 crossref_primary_10_1155_2019_6240505 crossref_primary_10_1111_pcmr_12657 crossref_primary_10_3390_ijms21207714 crossref_primary_10_17116_patol20208201168 crossref_primary_10_3390_ijms21218119 crossref_primary_10_1007_s12094_021_02734_2 crossref_primary_10_1371_journal_pone_0152523 crossref_primary_10_3390_biology11071014 crossref_primary_10_17116_patol20228405111 crossref_primary_10_1016_j_isci_2024_110701 crossref_primary_10_1111_cpr_13592 |
Cites_doi | 10.1158/1078-0432.CCR-06-1746 10.1053/j.gastro.2009.12.010 10.1016/j.yexcr.2010.02.045 10.1002/ijc.25358 10.1093/jjco/28.10.615 10.1016/j.gde.2009.01.003 10.1159/000226112 10.1038/modpathol.3800580 10.1002/ijc.23611 10.1007/s10549-012-1984-x 10.1111/j.1442-2050.2011.01211.x 10.4161/cbt.5.12.3354 10.1093/jnci/djh034 10.1002/ijc.2910400116 10.1007/s00418-012-0998-0 10.1158/1078-0432.CCR-06-2191 10.1007/BF00690602 10.1177/1066896912471851 10.1016/j.biocel.2006.11.005 10.5858/2009-0114-OA.1 10.1038/sj.bjc.6603651 10.2353/ajpath.2010.090526 10.1097/PAS.0b013e318184cd55 10.1158/1535-7163.MCT-11-0340 |
ContentType | Journal Article |
Copyright | 2013 The Korean Academy of Medical Sciences. 2013 |
Copyright_xml | – notice: 2013 The Korean Academy of Medical Sciences. 2013 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM ACYCR |
DOI | 10.3346/jkms.2013.28.9.1293 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Korean Citation Index |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1598-6357 |
EndPage | 1301 |
ExternalDocumentID | oai_kci_go_kr_ARTI_573314 PMC3763102 24015033 10_3346_jkms_2013_28_9_1293 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- 29K 2WC 3O- 5-W 53G 5GY 8JR 8XY 9ZL AAYXX ADBBV ADRAZ AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL CITATION CS3 D-I DIK DU5 E3Z EBS EF. EJD F5P FRP GROUPED_DOAJ GX1 HYE KQ8 M48 O5R O5S OK1 OVT PGMZT RNS RPM TR2 W2D XSB CGR CUY CVF ECM EIF NPM 7X8 5PM ACYCR |
ID | FETCH-LOGICAL-c438t-1b5a822d3cd762e651c0ff309051c01c9a8fa02a30396402314739d4d5ccf3963 |
IEDL.DBID | M48 |
ISSN | 1011-8934 1598-6357 |
IngestDate | Sun Mar 09 07:55:17 EDT 2025 Thu Aug 21 13:51:52 EDT 2025 Fri Jul 11 11:49:16 EDT 2025 Thu Apr 03 07:00:24 EDT 2025 Tue Jul 01 01:44:48 EDT 2025 Thu Apr 24 23:01:39 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 9 |
Keywords | Colorectal Neoplasms Cancer-Associated Fibroblast S100A4 α-Smooth Muscle Actin Podoplanin |
Language | English |
License | This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c438t-1b5a822d3cd762e651c0ff309051c01c9a8fa02a30396402314739d4d5ccf3963 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 G704-000345.2013.28.9.015 |
ORCID | 0000-0002-9711-6434 0000-0002-9397-0406 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3346/jkms.2013.28.9.1293 |
PMID | 24015033 |
PQID | 1431296316 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_573314 pubmedcentral_primary_oai_pubmedcentral_nih_gov_3763102 proquest_miscellaneous_1431296316 pubmed_primary_24015033 crossref_primary_10_3346_jkms_2013_28_9_1293 crossref_citationtrail_10_3346_jkms_2013_28_9_1293 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2013-09-01 |
PublicationDateYYYYMMDD | 2013-09-01 |
PublicationDate_xml | – month: 09 year: 2013 text: 2013-09-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Korea (South) |
PublicationPlace_xml | – name: Korea (South) |
PublicationTitle | Journal of Korean medical science |
PublicationTitleAlternate | J Korean Med Sci |
PublicationYear | 2013 |
Publisher | The Korean Academy of Medical Sciences 대한의학회 |
Publisher_xml | – name: The Korean Academy of Medical Sciences – name: 대한의학회 |
References | Ngan (10.3346/jkms.2013.28.9.1293_ref3) 2007; 96 Mesker (10.3346/jkms.2013.28.9.1293_ref20) 2007; 29 McAnulty (10.3346/jkms.2013.28.9.1293_ref18) 2007; 39 Tsujino (10.3346/jkms.2013.28.9.1293_ref2) 2007; 13 Boye (10.3346/jkms.2013.28.9.1293_ref27) 2010; 176 Grégoire (10.3346/jkms.2013.28.9.1293_ref5) 1995; 14 Martin (10.3346/jkms.2013.28.9.1293_ref6) 1987; 40 Tong (10.3346/jkms.2013.28.9.1293_ref22) 2012; 25 Schulte (10.3346/jkms.2013.28.9.1293_ref11) 2012; 138 Wang (10.3346/jkms.2013.28.9.1293_ref16) 2009; 33 Umar (10.3346/jkms.2013.28.9.1293_ref14) 2004; 96 Schoppmann (10.3346/jkms.2013.28.9.1293_ref24) 2012; 134 Ostman (10.3346/jkms.2013.28.9.1293_ref28) 2009; 19 Liotta (10.3346/jkms.2013.28.9.1293_ref7) 1983; 49 Kawase (10.3346/jkms.2013.28.9.1293_ref21) 2008; 123 Brennen (10.3346/jkms.2013.28.9.1293_ref30) 2012; 11 Yamanashi (10.3346/jkms.2013.28.9.1293_ref10) 2009; 77 Dumoff (10.3346/jkms.2013.28.9.1293_ref25) 2006; 19 Kono (10.3346/jkms.2013.28.9.1293_ref8) 2007; 31 Boland (10.3346/jkms.2013.28.9.1293_ref13) 1998; 58 American Joint Committee on Cancer (10.3346/jkms.2013.28.9.1293_ref15) 2009 Henry (10.3346/jkms.2013.28.9.1293_ref17) 2007; 13 Cheng (10.3346/jkms.2013.28.9.1293_ref4) 2002; 62 Sugimoto (10.3346/jkms.2013.28.9.1293_ref26) 2006; 5 Kitano (10.3346/jkms.2013.28.9.1293_ref9) 2010; 134 Vered (10.3346/jkms.2013.28.9.1293_ref12) 2010; 127 Pino (10.3346/jkms.2013.28.9.1293_ref29) 2010; 138 Nakayama (10.3346/jkms.2013.28.9.1293_ref19) 1998; 28 Foschini (10.3346/jkms.2013.28.9.1293_ref23) 2013; 21 Pietras (10.3346/jkms.2013.28.9.1293_ref1) 2010; 316 12183436 - Cancer Res. 2002 Aug 15;62(16):4767-72 6317982 - Lab Invest. 1983 Dec;49(6):636-49 14970275 - J Natl Cancer Inst. 2004 Feb 18;96(4):261-8 16528371 - Mod Pathol. 2006 May;19(5):708-16 20211171 - Exp Cell Res. 2010 May 1;316(8):1324-31 17196874 - Int J Biochem Cell Biol. 2007;39(4):666-71 20340130 - Int J Cancer. 2010 Sep 1;127(6):1356-62 20923309 - Arch Pathol Lab Med. 2010 Oct;134(10):1520-7 20026115 - Gastroenterology. 2010 Apr;138(4):1406-17 17404090 - Clin Cancer Res. 2007 Apr 1;13(7):2082-90 9823339 - Cancer Res. 1998 Nov 15;58(22):5248-57 22820858 - Histochem Cell Biol. 2012 Dec;138(6):847-60 3298078 - Int J Cancer. 1987 Jul 15;40(1):87-93 23349470 - Int J Surg Pathol. 2013 Apr;21(2):133-41 22323494 - Mol Cancer Ther. 2012 Feb;11(2):257-66 18546264 - Int J Cancer. 2008 Sep 1;123(5):1053-9 9839502 - Jpn J Clin Oncol. 1998 Oct;28(10):615-20 17726261 - Cell Oncol. 2007;29(5):387-98 22350732 - Breast Cancer Res Treat. 2012 Jul;134(1):237-44 21895849 - Dis Esophagus. 2012 Jan;25(1):72-80 17325702 - Br J Cancer. 2007 Mar 26;96(6):986-92 19211240 - Curr Opin Genet Dev. 2009 Feb;19(1):67-73 19556810 - Oncology. 2009;77(1):53-62 18971777 - Am J Surg Pathol. 2009 Jan;33(1):134-41 17671675 - Int J Oncol. 2007 Sep;31(3):501-8 8821094 - Cancer Metastasis Rev. 1995 Dec;14(4):339-50 20019188 - Am J Pathol. 2010 Feb;176(2):528-35 17363526 - Clin Cancer Res. 2007 Mar 15;13(6):1736-41 17106243 - Cancer Biol Ther. 2006 Dec;5(12):1640-6 |
References_xml | – volume: 58 start-page: 5248 year: 1998 ident: 10.3346/jkms.2013.28.9.1293_ref13 publication-title: Cancer Res – volume: 13 start-page: 1736 year: 2007 ident: 10.3346/jkms.2013.28.9.1293_ref17 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-06-1746 – volume: 138 start-page: 1406 year: 2010 ident: 10.3346/jkms.2013.28.9.1293_ref29 publication-title: Gastroenterology doi: 10.1053/j.gastro.2009.12.010 – volume: 316 start-page: 1324 year: 2010 ident: 10.3346/jkms.2013.28.9.1293_ref1 publication-title: Exp Cell Res doi: 10.1016/j.yexcr.2010.02.045 – volume: 127 start-page: 1356 year: 2010 ident: 10.3346/jkms.2013.28.9.1293_ref12 publication-title: Int J Cancer doi: 10.1002/ijc.25358 – volume: 28 start-page: 615 year: 1998 ident: 10.3346/jkms.2013.28.9.1293_ref19 publication-title: Jpn J Clin Oncol doi: 10.1093/jjco/28.10.615 – volume: 19 start-page: 67 year: 2009 ident: 10.3346/jkms.2013.28.9.1293_ref28 publication-title: Curr Opin Genet Dev doi: 10.1016/j.gde.2009.01.003 – volume: 31 start-page: 501 year: 2007 ident: 10.3346/jkms.2013.28.9.1293_ref8 publication-title: Int J Oncol – volume: 77 start-page: 53 year: 2009 ident: 10.3346/jkms.2013.28.9.1293_ref10 publication-title: Oncology doi: 10.1159/000226112 – volume: 19 start-page: 708 year: 2006 ident: 10.3346/jkms.2013.28.9.1293_ref25 publication-title: Mod Pathol doi: 10.1038/modpathol.3800580 – volume: 29 start-page: 387 year: 2007 ident: 10.3346/jkms.2013.28.9.1293_ref20 publication-title: Cell Oncol – volume: 123 start-page: 1053 year: 2008 ident: 10.3346/jkms.2013.28.9.1293_ref21 publication-title: Int J Cancer doi: 10.1002/ijc.23611 – volume: 62 start-page: 4767 year: 2002 ident: 10.3346/jkms.2013.28.9.1293_ref4 publication-title: Cancer Res – volume: 134 start-page: 237 year: 2012 ident: 10.3346/jkms.2013.28.9.1293_ref24 publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-012-1984-x – volume: 25 start-page: 72 year: 2012 ident: 10.3346/jkms.2013.28.9.1293_ref22 publication-title: Dis Esophagus doi: 10.1111/j.1442-2050.2011.01211.x – volume: 5 start-page: 1640 year: 2006 ident: 10.3346/jkms.2013.28.9.1293_ref26 publication-title: Cancer Biol Ther doi: 10.4161/cbt.5.12.3354 – volume: 96 start-page: 261 year: 2004 ident: 10.3346/jkms.2013.28.9.1293_ref14 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djh034 – volume: 40 start-page: 87 year: 1987 ident: 10.3346/jkms.2013.28.9.1293_ref6 publication-title: Int J Cancer doi: 10.1002/ijc.2910400116 – volume: 138 start-page: 847 year: 2012 ident: 10.3346/jkms.2013.28.9.1293_ref11 publication-title: Histochem Cell Biol doi: 10.1007/s00418-012-0998-0 – volume: 13 start-page: 2082 year: 2007 ident: 10.3346/jkms.2013.28.9.1293_ref2 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-06-2191 – volume: 49 start-page: 636 year: 1983 ident: 10.3346/jkms.2013.28.9.1293_ref7 publication-title: Lab Invest – volume: 14 start-page: 339 year: 1995 ident: 10.3346/jkms.2013.28.9.1293_ref5 publication-title: Cancer Metastasis Rev doi: 10.1007/BF00690602 – volume: 21 start-page: 133 year: 2013 ident: 10.3346/jkms.2013.28.9.1293_ref23 publication-title: Int J Surg Pathol doi: 10.1177/1066896912471851 – volume: 39 start-page: 666 year: 2007 ident: 10.3346/jkms.2013.28.9.1293_ref18 publication-title: Int J Biochem Cell Biol doi: 10.1016/j.biocel.2006.11.005 – volume: 134 start-page: 1520 year: 2010 ident: 10.3346/jkms.2013.28.9.1293_ref9 publication-title: Arch Pathol Lab Med doi: 10.5858/2009-0114-OA.1 – volume: 96 start-page: 986 year: 2007 ident: 10.3346/jkms.2013.28.9.1293_ref3 publication-title: Br J Cancer doi: 10.1038/sj.bjc.6603651 – volume: 176 start-page: 528 year: 2010 ident: 10.3346/jkms.2013.28.9.1293_ref27 publication-title: Am J Pathol doi: 10.2353/ajpath.2010.090526 – volume-title: Manual for staging of cancer year: 2009 ident: 10.3346/jkms.2013.28.9.1293_ref15 – volume: 33 start-page: 134 year: 2009 ident: 10.3346/jkms.2013.28.9.1293_ref16 publication-title: Am J Surg Pathol doi: 10.1097/PAS.0b013e318184cd55 – volume: 11 start-page: 257 year: 2012 ident: 10.3346/jkms.2013.28.9.1293_ref30 publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-11-0340 – reference: 20340130 - Int J Cancer. 2010 Sep 1;127(6):1356-62 – reference: 17196874 - Int J Biochem Cell Biol. 2007;39(4):666-71 – reference: 16528371 - Mod Pathol. 2006 May;19(5):708-16 – reference: 9823339 - Cancer Res. 1998 Nov 15;58(22):5248-57 – reference: 18546264 - Int J Cancer. 2008 Sep 1;123(5):1053-9 – reference: 18971777 - Am J Surg Pathol. 2009 Jan;33(1):134-41 – reference: 19556810 - Oncology. 2009;77(1):53-62 – reference: 20019188 - Am J Pathol. 2010 Feb;176(2):528-35 – reference: 22820858 - Histochem Cell Biol. 2012 Dec;138(6):847-60 – reference: 8821094 - Cancer Metastasis Rev. 1995 Dec;14(4):339-50 – reference: 17106243 - Cancer Biol Ther. 2006 Dec;5(12):1640-6 – reference: 3298078 - Int J Cancer. 1987 Jul 15;40(1):87-93 – reference: 9839502 - Jpn J Clin Oncol. 1998 Oct;28(10):615-20 – reference: 22323494 - Mol Cancer Ther. 2012 Feb;11(2):257-66 – reference: 20211171 - Exp Cell Res. 2010 May 1;316(8):1324-31 – reference: 19211240 - Curr Opin Genet Dev. 2009 Feb;19(1):67-73 – reference: 22350732 - Breast Cancer Res Treat. 2012 Jul;134(1):237-44 – reference: 12183436 - Cancer Res. 2002 Aug 15;62(16):4767-72 – reference: 21895849 - Dis Esophagus. 2012 Jan;25(1):72-80 – reference: 17671675 - Int J Oncol. 2007 Sep;31(3):501-8 – reference: 23349470 - Int J Surg Pathol. 2013 Apr;21(2):133-41 – reference: 17404090 - Clin Cancer Res. 2007 Apr 1;13(7):2082-90 – reference: 6317982 - Lab Invest. 1983 Dec;49(6):636-49 – reference: 14970275 - J Natl Cancer Inst. 2004 Feb 18;96(4):261-8 – reference: 20026115 - Gastroenterology. 2010 Apr;138(4):1406-17 – reference: 17325702 - Br J Cancer. 2007 Mar 26;96(6):986-92 – reference: 20923309 - Arch Pathol Lab Med. 2010 Oct;134(10):1520-7 – reference: 17363526 - Clin Cancer Res. 2007 Mar 15;13(6):1736-41 – reference: 17726261 - Cell Oncol. 2007;29(5):387-98 |
SSID | ssj0025523 |
Score | 2.2363815 |
Snippet | The interactions between the tumor microenvironment and tumor cells determine the behavior of the primary tumors. Whether cancer-associated fibroblasts (CAF)... |
SourceID | nrf pubmedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 1293 |
SubjectTerms | Actins - immunology Actins - metabolism Adult Aged Aged, 80 and over Antibodies - immunology Biomarkers, Tumor - metabolism Carcinoembryonic Antigen - blood Colorectal Neoplasms - diagnosis Colorectal Neoplasms - mortality Colorectal Neoplasms - pathology Disease-Free Survival Female Fibroblasts - cytology Fibroblasts - metabolism Humans Immunohistochemistry Lymphatic Metastasis Male Membrane Glycoproteins - immunology Membrane Glycoproteins - metabolism Middle Aged Neoplasm Staging Original Phenotype Prognosis S100 Calcium-Binding Protein A4 S100 Proteins - immunology S100 Proteins - metabolism 의학일반 |
Title | Podoplanin, α-Smooth Muscle Actin or S100A4 Expressing Cancer-Associated Fibroblasts Are Associated with Different Prognosis in Colorectal Cancers |
URI | https://www.ncbi.nlm.nih.gov/pubmed/24015033 https://www.proquest.com/docview/1431296316 https://pubmed.ncbi.nlm.nih.gov/PMC3763102 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART001802018 |
Volume | 28 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
ispartofPNX | Journal of Korean Medical Science, 2013, 28(9), 180, pp.1293-1301 |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dbtMwFLa2ISFuJv4pjMpIXM5VHLtpfIFQ1a3aQEWTRqXdWbHjjKqdsyWpNJ6DJ-FFeCbOyU-haHDBVaXGP1HOsc_32UffIeQtN8bJyEUsA7zLZKwSBrQ5ZU6ZzISAUHl94Db7FJ3M5YeL4cUO6aqith-wvJPaYT2pebEa3N58fQ8L_h0yToE3lMsrFN7mYhDGAzXACLZL7kFoipCNzeTmWgHgc9hk3HPOIFDLRobob4OgULDEEwEhtqLWri-yuwDpn3mVvwWq6UOy3yJMOm5c4hHZcf4xuT9r79CfkG9nwESvV4lf-EP64zs7v8rBWnS2LqE5HcP-52le0HMeBGNJj2-bTFl_SSfoIAXrDOpSOgWunRvA31UJ80HnX4_wfJcetdVXKnpW5JjRtygpjD6BDRc3WnjLZszyKZlPjz9PTlhbmoFZKeKKcTNMAFqkwqawm7poyG2QZSJAtS8bcKuSOEuCMIEAqSKJGnNyJFQq06G1GfwlnpE9n3v3gtAkdCoLRspIMIh1UmUOYGAahdZZY4XqkbD79Nq2uuVYPmOlgb-g6TSaTqPpdBhrpdF0PXK46XTdyHb8u_kbsKle2oVGuW38vcz1stBAKk41SkZyCW06i2tYgnivkniXr0tgTwIGiQSPeuR54wGbSTsH6pHRlm9sGuB820_84kst841bP8C_l__d8xV5ENbFOzAj7oDsVcXavQYIVZk-kIfTj_36AKJfL5Gf2vIcCA |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Podoplanin%2C+%CE%B1-Smooth+Muscle+Actin+or+S100A4+Expressing+Cancer-Associated+Fibroblasts+Are+Associated+with+Different+Prognosis+in+Colorectal+Cancers&rft.jtitle=Journal+of+Korean+medical+science&rft.au=Choi%2C+Song-Yi&rft.au=Sung%2C+Rohyun&rft.au=Lee%2C+Sang-Jeon&rft.au=Lee%2C+Taek-Gu&rft.date=2013-09-01&rft.pub=The+Korean+Academy+of+Medical+Sciences&rft.issn=1011-8934&rft.eissn=1598-6357&rft.volume=28&rft.issue=9&rft.spage=1293&rft.epage=1301&rft_id=info:doi/10.3346%2Fjkms.2013.28.9.1293&rft_id=info%3Apmid%2F24015033&rft.externalDocID=PMC3763102 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1011-8934&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1011-8934&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1011-8934&client=summon |